[S-1/CDDP combined neoadjuvant chemotherapy and surgical resection for advanced gastric cancer. Analysis of 12 patients with lymph node metastasis in Saitama Red Cross Hospital].
We evaluated the efficacy and safety of combination neoadjuvant chemotherapy consisting of S-1 and CDDP in patients with resectable advanced gastric cancer at Saitama Red Cross Hospital. Twelve patients who had lymph node metastasis preoperatively were enrolled. S-1 was given orally at 80 mg/m(2) for day 1-21 and 60 mg/m(2) of CDDP was administered on day 8. All patients were treated with a two-cycle protocol. The second cycle of the two-cycle protocol was started 14 days after the final oral administration of S-1 in the first cycle. There were no severe or unexpected adverse reactions. Preoperative response rate was 75.0%. Histological effect was judged to be grade 3 in 1 case and grade 2 in 2 cases. In the postoperative period, all patients received S-1-based adjuvant chemotherapy, but a relapse was determined in 4 patients. S-1/CDDP combination neoadjuvant chemotherapy in our hospital demonstrated high response and good compliance. However, we consider that the survival benefit of neoadjuvant chemotherapy for resectable advanced gastric cancer should be evaluated within the framework of clinical trials.